Beijing Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing 100083, China.
School of Biological Science and Medical Engineering, Beihang University, Beijing 100083, China.
Biomed Res Int. 2020 Sep 17;2020:4956946. doi: 10.1155/2020/4956946. eCollection 2020.
As the most common type of cancer in the world, hematological malignancies (HM) account for 10% of all annual cancer deaths and have attracted more attention. Conventional treatments, such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT), could relieve patients suffering HM. However, serious side effects and high costs bring patients both physical complaints and mental pressure. Recently, compared with conventional therapeutic strategies for HM patients, antibody-based immunotherapies, including cancer vaccines, oncolytic virus therapies, monoclonal antibody treatments, and CAR-T cell therapies, have displayed longer survival time and fewer adverse reactions, even though specific efficacy and safety of these antibody-based immunotherapies still need to be evaluated and improved. This review summarized the advantages of antibody-based immunotherapies over conventional treatments, as well as its existing difficulties and solutions, thereby enhancing the understanding and applications of antibody-based immunotherapies in HM treatment.
作为世界上最常见的癌症类型，血液系统恶性肿瘤（HM）占所有癌症死亡人数的 10%，因此受到了更多关注。化疗、放疗和造血干细胞移植（HSCT）等传统疗法可以缓解 HM 患者的痛苦。然而，严重的副作用和高昂的成本给患者带来了身体和心理上的双重压力。最近，与 HM 患者的传统治疗策略相比，抗体为基础的免疫疗法，包括癌症疫苗、溶瘤病毒疗法、单克隆抗体治疗和 CAR-T 细胞疗法，显示出更长的生存时间和更少的不良反应，尽管这些抗体为基础的免疫疗法的具体疗效和安全性仍需要进行评估和改进。本综述总结了抗体为基础的免疫疗法相对于传统治疗方法的优势，以及其目前存在的困难和解决方案，从而增强了对抗体为基础的免疫疗法在 HM 治疗中的理解和应用。
